Application of monocaprylic acid glycerol in preparing blood sugar lowering medicine or functional food
By using monoglyceride capric acid in high-fat diet and diabetes animal models, the metabolism of glucose and insulin is significantly improved, and the lack of blood sugar and improved insulin resistance in the prior art was solved, achieving better than the existing ones The therapeutic effect of the drug and its naturalness and safety have good application prospects.
Patent Information
- Application Number
- CN202410935514.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-12
- Publication Date
- 2024-11-12
- Estimated Expiration
- 2044-07-12
AI Technical Summary
In the prior art, research on the nutritional metabolism regulation function of monoglyceride capric acid is relatively scarce, and it is difficult to effectively utilize its effects of lowering blood sugar and improving insulin resistance, especially in the treatment of hyperglycemia and diabetes.
By using monoglyceride capric acid in high-fat dietary animal models and type 2 diabetes animal models, the body's tolerance to glucose is significantly improved, blood sugar and insulin content is reduced, insulin sensitivity is enhanced, liver glycolysis is promoted, and liver glycolysis is inhibited. Glycogenesis can achieve the effect of reducing blood sugar.
Monoglyceride capric acid showed significant effects of lowering blood sugar and improving insulin resistance in simulated hyperglycemia and diabetes models, even better than the commonly used hypoglycemia-lowering drug metformin, and is a naturally occurring edible substance, with high safety. Suitable for the preparation of drugs or functional foods for the treatment or adjuvant treatment of hyperglycemia and diabetes.
Smart Images

Figure CN118453564B_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the field of medical technology, and in particular to application of capric acid monoglyceride in preparing blood sugar-lowering medicines or functional foods. Background Art
[0002] Medium-chain fatty acid monoglyceride is a monoester formed by medium-chain fatty acids with a carbon chain length of 8-12 and glycerol. Glycerol monodecanoate (GMD) is the esterification product of capric acid (C10) and glycerol. It exists naturally in coconut oil, palm kernel oil and camphor seed oil. Its chemical formula is C 13 H 26 O4, molecular weight is 246.34. The industrial uses of monocaprylic acid glycerol include as an emulsifier, surfactant, lubricant and solvent. It can be used in cosmetics, food, pharmaceuticals and plastics.
[0003] Medium-chain fatty acid monoglycerides have a strong inhibitory effect on common food spoilage bacteria (including bacteria and fungi). Their antiseptic properties are better than general chemical preservatives, and they are safer, broader-spectrum and more efficient than chemical preservatives. Among them, caprylic acid monoglyceride (C8) and lauric acid monoglyceride (C12) are recognized as effective food emulsifiers and preservatives. Studies have shown that GMD has good antibacterial and antiviral effects, especially against Campylobacter, Salmonella and Escherichia coli.
[0004] Due to the characteristics of their chain, medium-chain fatty acids can be directly absorbed from the intestine into the portal vein and then metabolized in the liver. They can be used as a solubilizer and absorption enhancer to improve the oral bioavailability of drugs in vivo (Medium chain fatty acid metabolism and energy expenditure: Obesity treatment implications; DOI: 10.1016 / S0024-3205 (97) 01143-0). In terms of nutritional metabolism, medium-chain fatty acids can be quickly metabolized to produce energy in the body, have a good role in regulating metabolism, can increase energy consumption, and prevent metabolic syndrome. Medium-chain fatty acid monoglycerides have the characteristics of medium-chain fatty acids and are digested, absorbed, and metabolized very quickly in the body.
[0005] Studies have shown that caprylic acid monoglyceride has good effects in regulating intestinal flora, regulating inflammation, and increasing the content of short-chain fatty acids (Glycerol monocaprylate modulates gut microbiota and increases short-chain fatty acids production without adverse effects on metabolism and inflammation; DOI: 10.3390 / nu13051427). Lauric acid monoglyceride has also been shown to alleviate inflammation in mice fed a high-fat diet (Novel gut microbiota patterns involved in the attenuation of dextran sodium sulfate-induced mouse colitis mediated by glycerol monolauratevia inducing anti-inflammatory responses; DOI: 10.1128 / mBio.02148-21).
[0006] However, there is a lack of research on monocapric acid glyceryl. Exploring and developing the nutritional metabolism regulation function of monocapric acid glyceryl has practical value and significance. Summary of the invention
[0007] The purpose of the present invention is to provide a food-grade substance with the effect of lowering blood sugar and improving insulin resistance, which is used in the preparation of drugs for treating or assisting in the treatment of hyperglycemia, diabetes and other related diseases, or in the preparation of health foods that assist in lowering blood sugar.
[0008] To achieve the above object, the present invention adopts the following technical solution:
[0009] The invention provides application of capric acid monoglyceride in preparing medicine for treating hyperglycemia or diabetes or functional food for assisting in lowering blood sugar.
[0010] Hyperglycemia refers to the excessively high sugar content in the blood, which exceeds the normal range but does not meet the diagnostic criteria for diabetes, and is collectively referred to as impaired glucose tolerance. Experiments using a high-fat diet animal model to simulate high blood sugar caused by long-term intake of a high-fat diet have shown that capric monoglyceride can significantly and effectively improve the body's tolerance to glucose and alleviate high-fat diet-induced hyperglycemia, and its effect is better than that of the other two medium-chain fatty acid monoglycerides: caprylic monoglyceride and lauric monoglyceride.
[0011] Furthermore, the hyperglycemia is hyperglycemia induced by insulin β cell damage or insulin resistance.
[0012] The present invention found in an animal model experiment simulating type 2 diabetes that monocaprin has a strong ability to reduce postprandial blood sugar, and the effect is comparable to that of the commonly used hypoglycemic drug metformin.
[0013] Furthermore, the diabetes is type 2 diabetes.
[0014] The symptoms of diabetes mainly include polydipsia. The present invention has found that capric acid monoglyceride can significantly reduce the amount of water intake of diabetic mice, and this effect is different from metformin and is better than lauric acid monoglyceride.
[0015] The present invention shows that in high-fat diet animal models and type 2 diabetes animal models, monocapric acid glyceryl intervention can significantly improve the body's tolerance to glucose and insulin tolerance. In serum testing, monocapric acid glyceryl significantly reduces the body's blood sugar and insulin levels, significantly increases the content of glucagon-like peptide 1, enhances insulin sensitivity, and improves insulin resistance.
[0016] Mechanistic studies have shown that capric acid monoglyceride lowers blood sugar by promoting liver glycolysis and inhibiting gluconeogenesis. Gene expression level detection shows that capric acid monoglyceride can promote the glucokinase gene in the liver glycolysis pathway. GCK , insulin receptor gene INSR phosphoenolpyruvate carboxykinase gene in the gluconeogenesis pathway PEPCK , glucose-6-phosphatase catalytic subunit gene G6PC expression, thereby lowering blood sugar.
[0017] Capric acid monoglyceride exists naturally in edible oil, has high biological safety, and is expected to be developed into a drug for lowering blood sugar or a functional food for assisting in lowering blood sugar. The capric acid monoglyceride provided by the present invention is also suitable for use in people who take a high-fat diet for a long time or in obese people as a blood sugar regulator.
[0018] Preferably, the drug is in the form of an oral preparation. The specific dosage is adjusted according to the type of disease, disease severity, age and purpose of administration.
[0019] The present invention uses capric acid monoglyceride as an active ingredient to prepare a corresponding drug for lowering blood sugar, and the drug contains a pharmaceutically effective dose of capric acid monoglyceride. In addition, the drug may also contain a suitable drug carrier.
[0020] Specifically, the present invention provides a pharmaceutical composition for treating or assisting in the treatment of hyperglycemia or diabetes, comprising an effective dose of monocaprin and a pharmaceutically acceptable carrier.
[0021] The pharmaceutical composition is prepared by adding capric acid monoglyceride as the main active ingredient and a pharmaceutically acceptable carrier, and can be prepared according to the preparation method recorded in pharmacy. The drug can be in the form of a liquid preparation.
[0022] The present invention uses capric acid monoglyceride as an active ingredient to prepare a corresponding functional food for assisting in lowering blood sugar, and can also be added to food or beverages in the form of a food additive to improve the health level of users.
[0023] Specifically, the present invention provides a functional food for assisting in lowering blood sugar, comprising capric acid monoglyceride and excipients acceptable in food science. The functional food can be formulated in the form of capsules and the like.
[0024] Another object of the present invention is to provide a use of monocapric glyceride in the preparation of a glucagon-like peptide 1 agonist. Glucagon-like peptide 1 can stimulate insulin secretion, enhance insulin sensitivity, inhibit glucagon secretion, delay gastric emptying, reduce appetite, and thus reduce blood sugar and body weight.
[0025] Terminology Note:
[0026] The term "comprising" is an open expression, that is, it includes the contents specified in the present invention but does not exclude other contents.
[0027] The term "treating" refers in some embodiments to ameliorating a disease or condition (i.e., slowing or arresting or alleviating the development of a disease or at least one clinical symptom thereof). In other embodiments, it refers to alleviating or improving at least one physical parameter, including physical parameters that may not be perceived by the subject. In other embodiments, it refers to regulating a disease or condition physically (e.g., stabilizing a perceptible symptom) or physiologically (e.g., stabilizing a physical parameter), or both. In other embodiments, it refers to preventing or delaying the onset, onset, or worsening of a disease or condition.
[0028] The term "effective dose" refers to an amount of a compound that is sufficient to be effective in treating a disease when administered to a subject. The effective dose may vary with the severity of the disease, and the physical condition, age, weight, sex, etc. of the subject to be treated.
[0029] The term "pharmaceutically or edible acceptable carrier / excipient" refers to any preparation or carrier medium that can deliver an effective dose of the active substance of the present invention without interfering with the biological activity of the active substance and having no toxic side effects on the host or subject.
[0030] The present invention has the following beneficial effects:
[0031] The present invention discloses for the first time the function of monoglyceride caprate in lowering blood sugar and improving insulin resistance. Whether in the simulation of long-term high-fat diet or in the model of type 2 diabetes, monoglyceride caprate shows a significant effect of lowering blood sugar, can significantly improve the symptoms of insulin resistance, increase the secretion of glucagon-like peptide 1, activate the expression of liver glycolysis and insulin receptor-related genes, and inhibit the expression of liver gluconeogenesis pathway-related genes. Especially in type 2 diabetes, the hypoglycemic effect of monoglyceride caprate is equivalent to that of metformin, and its effect in regulating glucose tolerance and insulin tolerance is better than that of metformin, significantly improving the problem of polydipsia and polyphagia. Moreover, monoglyceride caprate is a naturally occurring edible substance with high safety. Therefore, it has good application prospects for the preparation of drugs for treating hyperglycemia and diabetes or functional foods that assist in lowering blood sugar. BRIEF DESCRIPTION OF THE DRAWINGS
[0032] Figure 1 This is the glucose tolerance test of mice fed with a high-fat diet in Example 1 at the 15th week of feeding, wherein Figure 1 A is the blood glucose change curve within 120 minutes after intraperitoneal injection of glucose; Figure 1 B is the area under the blood glucose curve within 120 minutes; Figure 1 C is the blood glucose level at 0 minutes before glucose injection. In the figure, * indicates a significant difference compared with the low-fat control group (NCD), # indicates a significant difference compared with the high-fat control group (HFD), ** indicates p < 0.01, *** indicates p < 0.001, # indicates p < 0.05, and ### indicates p < 0.001.
[0033] Figure 2 The changes in serum indicators of mice fed a high-fat diet in Example 1, Figure 2 A is the glucose content in serum; Figure 2 B is the insulin content in serum; Figure 2 C is the insulin resistance index calculated from glucose and insulin levels; Figure 2 D is the content of serum glucagon-like peptide 1. In the figure, * indicates a significant difference compared with the low-fat control group (NCD), # indicates a significant difference compared with the high-fat control group (HFD), * represents p < 0.05, ** represents p < 0.01, *** represents p < 0.001, # represents p < 0.05, ## represents p < 0.01, and ### represents p < 0.001.
[0034] Figure 3 is the gene expression in the liver of mice fed a high-fat diet in Example 1, wherein Figure 3 A is the glucokinase gene ( GCK ) Expression situation; Figure 3 B is the insulin receptor gene ( INSR ) Expression situation; Figure 3 C is the phosphoenolpyruvate carboxykinase gene ( PEPCK ) Expression situation; Figure 3 D is the gene for the catalytic subunit of glucose-6-phosphatase ( G6PC ) expression. In the figure, * indicates significant difference compared with the low-fat control group (NCD), # indicates significant difference compared with the high-fat control group (HFD), * represents p<0.05, ** represents p<0.01, *** represents p<0.001, # represents p<0.05, and ### represents p<0.001.
[0035] Figure 4 The effects of the three medium-chain fatty acid monoglycerides in Example 2 on the blood glucose of mice fed a high-fat diet, wherein Figure 4 A is the glucose content in serum; Figure 4 B is the insulin content in serum; Figure 4 C is the insulin resistance index calculated from glucose and insulin levels; Figure 4 D is the content of serum glucagon-like peptide 1. In the figure, # indicates a significant analysis with the low-fat control group (NCD), * indicates a significant analysis with the high-fat control group (HFD), $ indicates a significant analysis with the GMC1600 group, * represents p < 0.05, ** represents p < 0.01, *** represents p < 0.001, # represents p < 0.05, ## represents p < 0.01, ### represents p < 0.001, $ represents p < 0.05.
[0036] Figure 5 The blood sugar change trend and water intake of diabetic mice treated with GMD and GML. Figure 5 A. Figure 5 B shows the blood glucose change trend and average daily water intake of diabetic mice in 10 weeks of feeding (GMD experiment). In the figure, * indicates significant analysis with the normal mouse group (wt / wt), # indicates significant analysis with the diabetic mouse control group (db / db), $ indicates significant analysis with the metformin group (Metformin), *** represents p<0.001, ### represents p<0.001, $$ represents p<0.01, and $$$ represents p<0.001; Figure 5 C. Figure 5 D respectively represents the blood glucose change trend and average daily water intake of diabetic mice during 9 weeks of feeding (GML experiment). In the figure, * indicates a significant difference compared with the normal mouse group (wt / wt), # indicates a significant difference compared with the diabetic mouse control group (db / db), *** represents p<0.001, and ### represents p<0.001.
[0037] Figure 6The results of the glucose tolerance and insulin tolerance experiments on diabetic mice treated with GMD and GML are shown in Figure 2. Figure 6 A to Figure 6 D is the glucose tolerance test of diabetic mice at the 8th week of feeding and the insulin tolerance test (GMD test) at the 9th week of feeding. Specifically, Figure 6 A is the curve of blood sugar changes within 120 minutes after intraperitoneal injection of glucose; Figure 6 B is the area under the blood glucose curve within 120 minutes after intraperitoneal injection of glucose; Figure 6 C is the curve of blood glucose changes within 120 minutes after intraperitoneal injection of insulin; Figure 6 D is the area under the blood glucose curve within 120 minutes after intraperitoneal injection of insulin. In the figure, * indicates a significant analysis with the normal mouse group (wt / wt), # indicates a significant analysis with the diabetic mouse control group (db / db), *** represents p < 0.001, # represents p < 0.05, ## represents p < 0.01, and ### represents p < 0.001. Figure 6 E to Figure 6 H is the glucose tolerance test of diabetic mice at the 7th week of feeding and the insulin tolerance test (GML test) at the 8th week of feeding. Specifically, Figure 6 E is the curve of blood glucose changes within 120 minutes after intraperitoneal injection of glucose; Figure 6 F is the area under the blood glucose curve within 120 minutes after intraperitoneal injection of glucose; Figure 6 G is the curve of blood sugar changes within 120 minutes after intraperitoneal injection of insulin; Figure 6 H is the area under the blood glucose curve within 120 minutes after intraperitoneal injection of insulin. In the figure, * indicates a significant difference with the normal mouse group (wt / wt), # indicates a significant difference with the diabetic mouse control group (db / db), *** represents p<0.001, ## represents p<0.01, and ### represents p<0.001.
[0038] Figure 7 The changes of serum indicators in diabetic mice after GMD and GML treatment, among which Figure 7 A to Figure 7 D is the change of serum indexes in diabetic mice after feeding (GMD experiment). Specifically, Figure 7 A is the glucose content in serum; Figure 7 B is the insulin content in serum; Figure 7 C is the insulin resistance index calculated from the serum glucose and insulin levels; Figure 7D is the content of glucagon-like peptide 1 in serum. In the figure, * indicates a significant analysis with the normal mouse group (wt / wt), # indicates a significant analysis with the diabetic mouse control group (db / db), $ indicates a significant analysis with the metformin group (Metformin), * represents p < 0.05, ** represents p < 0.01, *** represents p < 0.001, # represents p < 0.05, ## represents p < 0.01, ### represents p < 0.001, and $$ represents p < 0.01. Figure 7 E to Figure 7 H is the change of serum indexes in diabetic mice after feeding (GML experiment). Specifically, Figure 7 E is the glucose content in serum; Figure 7 F is the insulin content in serum; Figure 7 G is the insulin resistance index calculated from the serum glucose and insulin levels; Figure 7 H is the content of serum glucagon-like peptide 1. In the figure, * indicates a significant difference with the normal mouse group (wt / wt), # indicates a significant difference with the diabetic mouse control group (db / db), ** indicates p<0.01, *** indicates p<0.001, # indicates p<0.05, and ### indicates p<0.001.
[0039] Figure 8 This is the gene expression in the liver of GMD-treated diabetic mice after feeding. Figure 8 A is the glucokinase gene ( GCK ) Expression situation; Figure 8 B is the insulin receptor gene ( INSR ) Expression situation; Figure 8 C is the phosphoenolpyruvate carboxykinase gene ( PEPCK ) Expression situation; Figure 8 D is the gene for the catalytic subunit of glucose-6-phosphatase ( G6PC ) expression. In the figure, * indicates significant analysis with the normal mouse group (wt / wt), # indicates significant analysis with the diabetic mouse control group (db / db), $ indicates significant analysis with the metformin group (Metformin), * represents p < 0.05, ** represents p < 0.01, *** represents p < 0.001, # represents p < 0.05, ## represents p < 0.01, ### represents p < 0.001, and $$ represents p < 0.01. DETAILED DESCRIPTION
[0040] The present invention will be further described below in conjunction with specific embodiments. The following embodiments are only used to illustrate the present invention and are not intended to limit the scope of application of the present invention. Without departing from the spirit and essence of the present invention, modifications or replacements made to the inventive method, steps or conditions all belong to the scope of the present invention.
[0041] The test methods used in the following examples are conventional methods unless otherwise specified; the materials and reagents used are commercially available, including capric monoglyceride CAS: 26402-22-2, lauric monoglyceride CAS: 40738-26-9, and caprylic monoglyceride CAS: 26402-26-6.
[0042] In the following examples, the common feed ingredients (g / 100g feed) include: casein 18.96, L-cystine 0.28, corn starch 29.86, maltodextrin 3.32, sucrose 33.17, cellulose 4.74, soybean oil 2.37, lard 1.90, mineral mixture 2.68, potassium citrate 1-hydrate 1.56, vitamin mixture 0.95, choline bitartrate 0.19, and a total calorie of 385kcal / 100g feed. The high-fat feed ingredients (g / 100g feed) include: casein 23.31, L-cystine 0.35, corn starch 8.48, maltodextrin 11.65, sucrose 20.14, cellulose 5.83, soybean oil 2.91, lard 20.68, mineral mixture 3.31, potassium citrate 1-hydrate 1.92, vitamin mixture 1.16, and choline bitartrate 0.23.
[0043] Example 1: Effects of capric monoglyceride (GMD) on mice fed a high-fat diet
[0044] 1. Experimental Grouping
[0045] Thirty-six 4-week-old healthy male C57BL / 6 mice (SPF) from Shanghai Slake Laboratory Animal Co., Ltd. were selected as experimental subjects. After 2 weeks of pre-feeding, all mice were randomly divided into 3 experimental groups, each of which was divided into 3 cages with 4 mice in each cage, and the mice were raised for 16 weeks. The detailed groups are as follows:
[0046] Low-fat control group (NCD): fed with normal feed and free access to water every day;
[0047] High-fat control group (HFD): fed with high-fat diet and free access to water every day;
[0048] Capric monoglyceride experimental group (GMD): fed with high-fat GMD feed (containing 1600 mg / kg of GMD on the basis of the above high-fat feed), with free access to water every day.
[0049] 2. Glucose tolerance test
[0050] At the 15th week, all mice were subjected to a glucose tolerance test: the mice were fasted for 12 hours in advance, and then a glucose solution was injected into the peritoneal vein of the mice at a dose of 2g / kg body weight. The blood glucose concentration of each mouse was measured using a blood glucose meter at 0, 30, 60, 90, and 120 minutes, and a blood glucose change curve was drawn, and the area under the blood glucose change curve was calculated. The results are as follows: Figure 1 shown.
[0051] like Figure 1 As shown in A, after intraperitoneal injection of glucose solution, the blood glucose levels of all mice showed an upward trend within 30 minutes and began to slowly decline within the next 90 minutes, while the blood glucose levels of the NCD group and the GMD group were always lower than that of the HFD group. Figure 1 B. Figure 1 As shown in C, the areas under the glucose tolerance test curve and the blood glucose levels at 0 minutes in the NCD and GMD groups were significantly lower than those in the HFD group.
[0052] Long-term high-fat diet induces symptoms of hyperglycemia and insulin resistance in mice. The results of glucose tolerance experiments show that GMD can significantly improve the response and regulation of blood sugar in mice and reduce the hyperglycemia caused by a high-fat diet.
[0053] 3. Serum index test
[0054] The mice were raised for 16 weeks. At the end of the experiment, blood was collected from the eye sockets of the mice, serum was collected, and the mice were euthanized. The livers of the mice were then collected and cryopreserved.
[0055] The blood glucose level in mouse serum was measured using a kit from Nanjing Jiancheng Bioengineering Institute.
[0056] The ELISA kit of Wuhan Gene Beauty Biotechnology Co., Ltd. was used to measure the insulin content and glucagon-like peptide 1 content in mouse serum. Glucagon-like peptide 1 is an intestinal hormone secreted by intestinal L cells, which can suppress the appetite of organisms, enhance insulin sensitivity, and regulate blood sugar in the body by affecting multiple receptors of the body.
[0057] The insulin resistance index was calculated based on the blood glucose level and insulin level according to the following formula: insulin level × blood glucose concentration / 22.5.
[0058] The results are as follows Figure 2 As shown in Figure 2, compared with the NCD group, the serum glucose level, serum insulin level and insulin resistance index in the HFD group were significantly increased ( Figure 2 A. Figure 2 B. Figure 2 C), the level of glucagon-like peptide 1 decreased significantly ( Figure 2D), indicating that the animal model of high-fat diet-induced hyperglycemia and insulin resistance was successfully established.
[0059] Compared with the HFD group, the serum glucose level, serum insulin level and insulin resistance index of the GMD group were significantly reduced ( Figure 2 A. Figure 2 B. Figure 2 C), while the content of glucagon-like peptide 1 was significantly increased, which was comparable to that of the NCD group ( Figure 2 D).
[0060] The above results show that GMD can significantly increase glucagon-like peptide 1 in mice fed a high-fat diet, lower blood sugar and alleviate insulin resistance.
[0061] 4. Liver gene expression detection
[0062] Real-time fluorescence quantitative PCR was used to detect gene expression in the liver: RNA in the liver was extracted using Trizol, and the concentration and purity of RNA were determined using a Nanodrop ND-2000 spectrophotometer. The extracted RNA was then reverse transcribed into cDNA using a reverse transcription kit from Nanjing Novozymes, and the glucokinase gene was detected on a LightCycler 480 instrument using Novozymes' SYBR fluorescent dye ( GCK )、Insulin receptor gene( INSR ), phosphoenolpyruvate carboxykinase gene ( PEPCK )、Glucose-6-phosphatase catalytic subunit gene( G6PC The primers used for real-time fluorescence quantitative PCR are shown in Table 1. Figure 3 shown.
[0063] Table 1. Real-time fluorescence quantitative PCR primers
[0064] Forward primer (5'-3') Reverse primer (5'-3') TAGGAGCAGCCATGAGAT CGAAGTTGTAGCCGAAGA TCTGTCCCGGATCTACCTTG GTAGAATCCAAGCGCGAAAC CAGTTTGTGGAACGGTGCTG CATAGGAGCGGCGGATCTTT TCCCTGTAAGGCACGAAGAC ACGATGTTGTTCCCTTCTGC
[0065] GCK is the first rate-limiting enzyme in glucose metabolism. It can convert glucose into glucose-6-phosphate, which is the first step in glycolysis and glycogen synthesis. GCK can also act as a glucose sensor to regulate insulin secretion and energy balance. Figure 3 A The results showed that compared with the NCD group, the HFD group GCK The gene expression of GCK Gene expression was significantly increased, indicating that GMD intake could accelerate glucose metabolism in mice fed a high-fat diet.
[0066] INSRThe gene is a gene that encodes the insulin receptor, which is a transmembrane receptor tyrosine kinase that can bind to insulin or other ligands, thereby activating the insulin signaling pathway and regulating the uptake and release of glucose. Figure 3 The results of B showed that the GMD group INSR The gene was significantly higher than that in the HFD group, indicating that the intake of GMD can significantly activate the insulin receptor gene and promote the role of insulin in regulating blood sugar.
[0067] PEPCK The gene is a gene encoding phosphoenolpyruvate carboxykinase, which is an important enzyme involved in gluconeogenesis. It can convert oxaloacetate into phosphoenolpyruvate to produce glucose. G6PC The gene is also a key gene in the gluconeogenesis pathway, encoding the catalytic subunit of glucose-6-phosphatase, a key enzyme in glucose homeostasis. Figure 3 C. Figure 3 The results of D showed that compared with the NCD group, the HFD group PEPCK Genes and G6PC The expression of genes in the GMD group was significantly increased compared with the HFD group. PEPCK Genes and G6PC The expression of the gene was significantly reduced, indicating that GMD intake suppressed the PEPCK and G6PC The expression of β-catenin decreased hepatic gluconeogenesis in mice fed a high-fat diet.
[0068] Example 2: Effects of three medium-chain fatty acid monoglycerides on blood glucose in mice fed a high-fat diet
[0069] 1. Experimental Grouping
[0070] 60 4-week-old healthy male C57BL / 6 mice (SPF) from Shanghai Slake Laboratory Animal Co., Ltd. were selected as experimental subjects. After 2 weeks of pre-feeding, all mice were randomly divided into 5 experimental groups, each of which was divided into 3 cages with 4 mice in each cage, and the mice were raised for 16 weeks. The detailed groups are as follows:
[0071] Low-fat control group (NCD): fed with normal feed and free access to water every day;
[0072] High-fat control group (HFD): fed with high-fat diet and free access to water every day;
[0073] Caprylic monoglyceride experimental group (GMC): fed with high-fat GMC feed (containing 1600 mg / kg of GMC), with free access to water every day;
[0074] Capric monoglyceride experimental group (GMD): fed with high-fat GMD feed (containing 1600 mg / kg of GMD), with free access to water every day;
[0075] Monolaurin experimental group (GML): fed with high-fat GML feed (containing 1600 mg / kg of GML), with free access to water every day.
[0076] 2. Serum index test
[0077] The mice were raised for 16 weeks. At the end of the experiment, blood was collected from the eye sockets of the mice, serum was collected, and the mice were euthanized. The livers of the mice were then collected and cryopreserved.
[0078] The blood glucose level in mouse serum was measured using a kit from Nanjing Jiancheng Bioengineering Institute.
[0079] The ELISA kit of Wuhan Gene Beauty Biotechnology Co., Ltd. was used to measure the insulin content and glucagon-like peptide 1 content in mouse serum. The insulin resistance index was calculated according to the blood glucose content and insulin content according to the following formula: insulin content × blood glucose concentration / 22.5.
[0080] The results are as follows Figure 4 As shown in Figure 2, compared with the NCD group, the serum glucose level, serum insulin level and insulin resistance index in the HFD group were significantly increased ( Figure 4 A. Figure 4 B. Figure 4 C), the level of glucagon-like peptide 1 decreased significantly ( Figure 4 D), indicating that the animal model of high-fat diet-induced hyperglycemia and insulin resistance was successfully established.
[0081] Compared with the HFD group, the serum glucose level, serum insulin level and insulin resistance index of the GMD group and the GML group were significantly reduced ( Figure 4 A. Figure 4 B. Figure 4 C), while the content of glucagon-like peptide 1 was significantly increased, which was comparable to that of the NCD group ( Figure 4 D), among which the GMD group had the strongest effect in reducing blood sugar and insulin resistance index.
[0082] The above results show that GMD can significantly increase glucagon-like peptide 1 in mice fed a high-fat diet, lower blood sugar and alleviate insulin resistance, and its effect is the most significant among medium-chain fatty acid monoglycerides.
[0083] Example 3: Effects of capric monoglyceride (GMD) on diabetic mice
[0084] 1. Select 12 C57BLKS / JGpt mice and 36 C57BLKS / JGpt-dbdb mice from Jiangsu Jicui Pharmaceutical Biotechnology Co., Ltd. C57BLKS / JGpt-dbdb is a mouse with a mutation in the C57BLKS / JGpt leptin receptor gene, which is a typical type 2 diabetes research model mouse. After one week of pre-feeding, all mice were randomly divided into 4 experimental groups, each of which was divided into 3 cages, 4 mice per cage, and fed for 10 weeks. The detailed grouping is as follows:
[0085] Normal mouse control group (wt / wt): C57BLKS / JGpt mice were fed with normal feed and had free access to water every day; control solution (50% PEG400 + 50% saline, 5 mL / kg body weight) was gavaged daily;
[0086] Diabetic mouse control group (db / db): C57BLKS / JGpt-dbdb mice were fed with normal feed and had free access to water every day; they were gavaged with control solution (50% PEG400 + 50% saline, 5 mL / kg body weight) every day;
[0087] Metformin experimental group (Metformin): C57BLKS / JGpt-dbdb mice were fed with ordinary feed and had free access to water every day; they were gavaged with metformin solution at a dose of 200 mg / kg body weight every day (200 mg metformin was dissolved in 2.5 mL PEG400 + 2.5 mL normal saline, and gavage was performed at a dose of 5 mL / kg body weight);
[0088] Capric monoglyceride experimental group (GMD): C57BLKS / JGpt-dbdb mice were fed with ordinary feed and had free access to water every day; they were gavaged with GMD solution at a dose of 160 mg / kg body weight every day (160 mg GMD was suspended in 2.5 mL PEG400 + 2.5 mL normal saline, and gavage was performed at a dose of 5 mL / kg body weight).
[0089] 2. Measure the postprandial blood sugar of mice regularly every week and record the amount of water they drink every day. Figure 5 shown.
[0090] like Figure 5As shown in A, during the 10 weeks of feeding, the blood sugar level of the db / db mouse group remained at a high level, and as the feeding time went on, the blood sugar level continued to increase, with the average blood sugar level exceeding 30mmol / L in the later period. The daily blood sugar levels of the metformin experimental group and the GMD experimental group were significantly lower than those of the db / db mouse group, and the blood sugar levels were able to maintain a stable trend during the feeding period. Metformin is a well-known hypoglycemic drug used in type 2 diabetes. In diabetic model mice, the blood sugar-lowering effect of GMD is almost the same as that of metformin.
[0091] Diabetic mice will have a clear sense of thirst and need to drink a lot of water. Figure 5 The results of B showed that GMD significantly reduced the daily water intake of diabetic mice, indicating that diabetes was improved.
[0092] 3. Glucose tolerance test
[0093] At the 8th week of feeding, all mice were subjected to a glucose tolerance test: the mice were fasted for 12 hours in advance, and then a glucose solution was injected into the peritoneal vein of the mice at a dose of 1.5 g / kg body weight. The blood glucose concentration of each mouse was measured using a blood glucose meter at 0, 30, 60, 90, and 120 minutes, and a blood glucose change curve was drawn, and the area under the blood glucose change curve was calculated. The results are shown in Figure 2. Figure 6 shown.
[0094] like Figure 6 As shown in A, after intraperitoneal injection of glucose solution, the blood glucose of all mice showed an upward trend within 30 minutes, and then began to slowly decline within the next 90 minutes. The blood glucose of the wt / wt group was always at a low level, and the blood glucose of the metformin experimental group and the GMD experimental group was always lower than that of the db / db mouse group. Figure 6 The results of B showed that the areas under the glucose tolerance test curves of the metformin experimental group and the GMD experimental group were significantly lower than that of the db / db mouse group, among which the GMD experimental group was the lowest among diabetic mice, and the effect exceeded that of the metformin experimental group.
[0095] 4. Insulin tolerance test
[0096] In the 9th week of feeding, all mice were subjected to an insulin tolerance test: the mice were fasted for 12 hours in advance, and then insulin was injected into the peritoneal vein of the mice at a dose of 2U / kg body weight. The blood glucose concentration of each mouse was measured using a blood glucose meter at 0, 30, 60, 90, and 120 minutes, and a blood glucose change curve was drawn, and the area under the blood glucose change curve was calculated. The results are as follows: Figure 6 shown.
[0097] like Figure 6As shown in C, after intraperitoneal injection of insulin, the blood glucose of diabetic mice showed a downward trend after a brief increase. Similar to the results of the glucose tolerance test, the blood glucose levels of the metformin experimental group and the GMD experimental group were always lower than that of the db / db mouse group. Figure 6 The results of D showed that the areas under the insulin tolerance test curves of the metformin experimental group and the GMD experimental group were significantly lower than that of the db / db mouse group, among which the GMD experimental group was also the lowest among diabetic mice, and the effect was also better than that of the metformin experimental group.
[0098] The results of glucose tolerance tests and insulin tolerance tests show that GMD is significantly effective in regulating blood sugar in diabetic mice, and its effect even exceeds that of metformin, a commonly used hypoglycemic drug.
[0099] 5. Effects of capric monoglyceride (GMD) on serum parameters of diabetic mice
[0100] After 10 weeks of feeding, blood was collected from the mouse orbits, serum was collected, and the mice were euthanized. The mouse livers were then collected and frozen for storage. The blood glucose content in the mouse serum was determined using the kit from Nanjing Jiancheng Bioengineering Institute, and the insulin content and glucagon-like peptide 1 content in the mouse serum were determined using the ELISA kit from Wuhan Gene Beauty Biotechnology Co., Ltd. The insulin resistance index was calculated based on the blood glucose content and insulin content according to the following formula: insulin content × blood glucose concentration / 22.5. The results are as follows: Figure 7 shown.
[0101] like Figure 7 A to Figure 7 As shown in D, compared with the db / db mouse group, the serum glucose content and insulin resistance index of the Metformin experimental group and the GMD experimental group were significantly reduced, and the content of glucagon-like peptide 1 was significantly increased; the GMD experimental group significantly reduced the serum insulin content, and the content of glucagon-like peptide 1 was also significantly higher than that of the Metformin experimental group.
[0102] The results showed that GMD could significantly increase the content of glucagon-like peptide 1 in diabetic mice, lower blood sugar and alleviate insulin resistance.
[0103] 6. Liver gene expression detection
[0104] Consistent with the high-fat diet mouse experiment above, a fluorescence quantitative qPCR experiment was used to detect the glucose kinase gene in the liver ( GCK )、Insulin receptor gene( INSR ), phosphoenolpyruvate carboxykinase gene ( PEPCK )、Glucose-6-phosphatase catalytic subunit gene( G6PC )’s expression.
[0105] like Figure 8 As shown, compared with the db / db mouse group, the glycolytic genes in the metformin experimental group and the GMD experimental group GCK The expression of Figure 8 A), GMD experimental group INSR The expression of Figure 8 B); At the same time, compared with the db / db mouse group, both the metformin experimental group and the GMD experimental group significantly inhibited the expression of gluconeogenesis genes PEPCK ( Figure 8 C) and G6PC ( Figure 8 D) expression.
[0106] The results showed that GMD could significantly promote liver glycolysis in diabetic mice, activate the expression of insulin receptor genes, and inhibit the expression of liver gluconeogenesis-related genes, thereby achieving the effect of lowering blood sugar.
[0107] Comparative Example 1: Effects of lauric acid monoglyceride (GML) on diabetic mice
[0108] 1. Select 12 C57BLKS / JGpt mice and 36 C57BLKS / JGpt-dbdb mice from Jiangsu Jicui Pharmaceutical Biotechnology Co., Ltd. After 1 week of pre-feeding, all mice were randomly divided into 4 experimental groups, each of which was divided into 3 cages with 4 mice in each cage, and the mice were fed for 9 weeks. The detailed groups are as follows:
[0109] Normal mouse control group (wt / wt): fed with normal feed and free access to water every day; gavaged with control solution (50% PEG400 + 50% saline, 5 mL / kg body weight) every day;
[0110] Diabetic mouse control group (db / db): fed with normal feed and free access to water every day; gavaged with control solution (50% PEG400 + 50% saline, 5 mL / kg body weight) every day;
[0111] Metformin experimental group (db / db +Metformin): fed with ordinary feed, free access to water every day; gavage with metformin solution at a dose of 200 mg / kg body weight every day (200 mg metformin dissolved in 2.5 mL PEG400 + 2.5 mL normal saline, gavage at a dose of 5 mL / kg body weight);
[0112] The monolaurin experimental group (db / db + GML) was fed with ordinary feed and had free access to water every day; the mice were gavaged with GML solution at a dose of 160 mg / kg body weight every day (160 mg GML was suspended in 2.5 mL PEG400 + 2.5 mL normal saline, and the dosage was 5 mL / kg body weight during gavage).
[0113] 2. Measure the postprandial blood sugar of mice regularly every week and record the amount of water they drink every day. Figure 5 shown.
[0114] like Figure 5 As shown in C, during the 9 weeks of feeding, the blood glucose level of the db / db mouse group remained at a high level, and showed a trend of continuous increase in blood glucose level as the feeding time went on. The daily blood glucose levels of the metformin experimental group and the GML experimental group were significantly lower than those of the db / db mouse group. Figure 5 The results of D showed that GML and metformin significantly reduced the daily water intake of diabetic mice, indicating that diabetes was improved.
[0115] The results showed that GML could improve the daily blood sugar of diabetic mice and reduce water intake, but the effect was not as good as metformin. Overall, GML was not as effective as GMD in improving the blood sugar of diabetic mice.
[0116] 3. Glucose tolerance test
[0117] At the 7th week of feeding, all mice were subjected to a glucose tolerance test: the mice were fasted for 12 hours in advance, and then a glucose solution was injected into the peritoneal vein of the mice at a dose of 1.5 g / kg body weight. The blood glucose concentration of each mouse was measured using a blood glucose meter at 0, 30, 60, 90, and 120 minutes, and a blood glucose change curve was drawn, and the area under the blood glucose change curve was calculated. The results are shown in Figure 2. Figure 6 shown.
[0118] like Figure 6 As shown in E, after intraperitoneal injection of glucose solution, the blood glucose levels of all mice showed an increasing trend within 30 minutes. In the following 90 minutes, the blood glucose levels of the metformin experimental group and the GML experimental group were always lower than that of the db / db mouse group. Figure 6 The results of F showed that the areas under the glucose tolerance test curves of the metformin experimental group and the GML experimental group were significantly lower than those of the db / db mouse group, among which the metformin experimental group was the lowest among diabetic mice.
[0119] 4. Insulin tolerance test
[0120] In the 8th week of feeding, all mice were subjected to an insulin tolerance test: the mice were fasted for 12 hours in advance, and then insulin was injected into the peritoneal vein of the mice at a dose of 2U / kg body weight. The blood glucose concentration of each mouse was measured at 0, 30, 60, 90, and 120 minutes using a blood glucose meter, and the blood glucose change curve was drawn and the area under the blood glucose change curve was calculated. The results are shown in Figure 2. Figure 6 shown.
[0121] like Figure 6 As shown in G, after intraperitoneal injection of insulin, the blood glucose levels of the metformin experimental group and the GML experimental group were always lower than that of the db / db mouse group. Figure 6 The results of H showed that the areas under the insulin tolerance test curves of the metformin experimental group and the GML experimental group were significantly lower than that of the db / db mouse group, among which the metformin experimental group was also the lowest among diabetic mice.
[0122] From the results of glucose tolerance test and insulin tolerance test, it can be seen that GML has a significant effect on blood sugar regulation in diabetic mice, but with the effect of metformin as a reference, its effect on regulating blood sugar in diabetic mice is not as good as GMD.
[0123] 5. Effects of lauric acid monoglyceride (GML) on serum parameters of diabetic mice
[0124] After 9 weeks of feeding, blood was collected from the mouse orbits, serum was collected, and the mice were euthanized. The mouse livers were then collected and frozen for storage. The blood glucose content in the mouse serum was determined using the kit from Nanjing Jiancheng Bioengineering Institute, and the insulin content and glucagon-like peptide 1 content in the mouse serum were determined using the ELISA kit from Wuhan Gene Beauty Biotechnology Co., Ltd. The insulin resistance index was calculated based on the blood glucose content and insulin content according to the following formula: insulin content × blood glucose concentration / 22.5. The results are as follows: Figure 7 shown.
[0125] like Figure 7 E to Figure 7 As shown in Figure 3, compared with the db / db mouse group, the serum glucose level and insulin resistance index of the metformin experimental group and the GML experimental group were significantly reduced, while the glucagon-like peptide 1 level was significantly increased, among which there was no significant difference in the glucagon-like peptide 1 level between the metformin experimental group and the GML experimental group.
[0126] The results showed that GML could significantly lower blood sugar, relieve insulin resistance, and increase the content of glucagon-like peptide 1 in diabetic mice, but the effect of increasing the content of glucagon-like peptide 1 was not as good as GMD.
Claims
1. Use of capric monoglyceride in the preparation of a drug for treating hyperglycemia or diabetes or a functional food for assisting hyperglycemia or diabetes in lowering blood sugar, It is characterized in that The hyperglycemia is hyperglycemia induced by insulin resistance; the diabetes is type 2 diabetes, and the symptoms include polydipsia and a significant decrease in the level of glucagon-like peptide 1 in serum.
2. The use according to claim 1, It is characterized in that The capric acid monoglyceride improves the body's tolerance to glucose and insulin tolerance, increases the content of glucagon-like peptide 1, enhances insulin sensitivity, and improves insulin resistance.
3. The use according to claim 1, It is characterized in that Decanoic acid monoglyceride promotes the expression of glucose kinase gene and insulin receptor gene in the liver glycolysis pathway, and inhibits the expression of phosphoenolpyruvate carboxykinase gene and glucose-6-phosphatase catalytic subunit gene in the gluconeogenesis pathway, thereby lowering blood sugar.
4. The use according to claim 1, It is characterized in that The preparation form of the drug is an oral preparation.
